Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/PTEN_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/PTEN_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PTEN_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/PTEN_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/PTEN_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PTEN_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/PTEN_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/PTEN_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PTEN_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:19030502 | Colorectum | MSS | regulation of proteolysis involved in cellular protein catabolic process | 82/3467 | 221/18723 | 4.97e-11 | 5.64e-09 | 82 |
GO:20012332 | Colorectum | MSS | regulation of apoptotic signaling pathway | 116/3467 | 356/18723 | 1.02e-10 | 1.06e-08 | 116 |
GO:00458622 | Colorectum | MSS | positive regulation of proteolysis | 119/3467 | 372/18723 | 2.14e-10 | 2.09e-08 | 119 |
GO:19033202 | Colorectum | MSS | regulation of protein modification by small protein conjugation or removal | 82/3467 | 242/18723 | 7.49e-09 | 4.63e-07 | 82 |
GO:20000582 | Colorectum | MSS | regulation of ubiquitin-dependent protein catabolic process | 61/3467 | 164/18723 | 1.28e-08 | 7.61e-07 | 61 |
GO:00508212 | Colorectum | MSS | protein stabilization | 68/3467 | 191/18723 | 1.53e-08 | 8.81e-07 | 68 |
GO:19033642 | Colorectum | MSS | positive regulation of cellular protein catabolic process | 57/3467 | 155/18723 | 6.01e-08 | 3.15e-06 | 57 |
GO:00108102 | Colorectum | MSS | regulation of cell-substrate adhesion | 73/3467 | 221/18723 | 1.56e-07 | 7.16e-06 | 73 |
GO:00313962 | Colorectum | MSS | regulation of protein ubiquitination | 70/3467 | 210/18723 | 1.88e-07 | 8.26e-06 | 70 |
GO:00343292 | Colorectum | MSS | cell junction assembly | 120/3467 | 420/18723 | 2.51e-07 | 1.07e-05 | 120 |
GO:00076232 | Colorectum | MSS | circadian rhythm | 69/3467 | 210/18723 | 4.22e-07 | 1.67e-05 | 69 |
GO:00420602 | Colorectum | MSS | wound healing | 119/3467 | 422/18723 | 5.93e-07 | 2.24e-05 | 119 |
GO:00160552 | Colorectum | MSS | Wnt signaling pathway | 124/3467 | 444/18723 | 6.06e-07 | 2.26e-05 | 124 |
GO:01987382 | Colorectum | MSS | cell-cell signaling by wnt | 124/3467 | 446/18723 | 7.83e-07 | 2.77e-05 | 124 |
GO:00485112 | Colorectum | MSS | rhythmic process | 89/3467 | 298/18723 | 1.17e-06 | 3.96e-05 | 89 |
GO:19030522 | Colorectum | MSS | positive regulation of proteolysis involved in cellular protein catabolic process | 48/3467 | 133/18723 | 1.21e-06 | 4.06e-05 | 48 |
GO:00315892 | Colorectum | MSS | cell-substrate adhesion | 104/3467 | 363/18723 | 1.35e-06 | 4.51e-05 | 104 |
GO:01501152 | Colorectum | MSS | cell-substrate junction organization | 39/3467 | 101/18723 | 1.74e-06 | 5.60e-05 | 39 |
GO:00097432 | Colorectum | MSS | response to carbohydrate | 77/3467 | 253/18723 | 2.75e-06 | 8.25e-05 | 77 |
GO:00342842 | Colorectum | MSS | response to monosaccharide | 70/3467 | 225/18723 | 3.27e-06 | 9.57e-05 | 70 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PTEN | SNV | Missense_Mutation | rs121909229 | c.389N>A | p.Arg130Gln | p.R130Q | P60484 | protein_coding | deleterious(0.02) | probably_damaging(0.998) | TCGA-A2-A4RX-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PTEN | SNV | Missense_Mutation | | c.404T>A | p.Ile135Lys | p.I135K | P60484 | protein_coding | deleterious(0.03) | probably_damaging(0.999) | TCGA-A7-A26G-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD |
PTEN | SNV | Missense_Mutation | rs121909229 | c.389G>A | p.Arg130Gln | p.R130Q | P60484 | protein_coding | deleterious(0.02) | probably_damaging(0.998) | TCGA-A7-A4SC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
PTEN | SNV | Missense_Mutation | | c.593N>A | p.Met198Lys | p.M198K | P60484 | protein_coding | deleterious(0) | benign(0.285) | TCGA-AC-A2FF-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
PTEN | SNV | Missense_Mutation | | c.384N>C | p.Lys128Asn | p.K128N | P60484 | protein_coding | deleterious(0.03) | probably_damaging(0.998) | TCGA-AN-A0XW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
PTEN | SNV | Missense_Mutation | | c.28N>C | p.Ser10Arg | p.S10R | P60484 | protein_coding | deleterious(0) | benign(0.188) | TCGA-AR-A1AJ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PTEN | SNV | Missense_Mutation | rs786201995 | c.70G>A | p.Asp24Asn | p.D24N | P60484 | protein_coding | deleterious(0) | benign(0.012) | TCGA-AR-A1AM-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
PTEN | SNV | Missense_Mutation | | c.367C>G | p.His123Asp | p.H123D | P60484 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AR-A24Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
PTEN | SNV | Missense_Mutation | | c.370N>A | p.Cys124Ser | p.C124S | P60484 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AR-A2LL-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
PTEN | SNV | Missense_Mutation | rs121909229 | c.389N>A | p.Arg130Gln | p.R130Q | P60484 | protein_coding | deleterious(0.02) | probably_damaging(0.998) | TCGA-AR-A5QQ-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | carboplatin | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5728 | PTEN | PTEN FAMILY, ENZYME, PROTEIN PHOSPHATASE, DRUG RESISTANCE, CLINICALLY ACTIONABLE, KINASE | | PI3KBETA INHIBITOR AZD8186 | | 25544636 |
5728 | PTEN | PTEN FAMILY, ENZYME, PROTEIN PHOSPHATASE, DRUG RESISTANCE, CLINICALLY ACTIONABLE, KINASE | | TEMSIROLIMUS | TEMSIROLIMUS | 11504908,23674493 |
5728 | PTEN | PTEN FAMILY, ENZYME, PROTEIN PHOSPHATASE, DRUG RESISTANCE, CLINICALLY ACTIONABLE, KINASE | | Temsirolimus | TEMSIROLIMUS | 27016228 |
5728 | PTEN | PTEN FAMILY, ENZYME, PROTEIN PHOSPHATASE, DRUG RESISTANCE, CLINICALLY ACTIONABLE, KINASE | | PF-04691502 | PF-04691502 | 21750219 |
5728 | PTEN | PTEN FAMILY, ENZYME, PROTEIN PHOSPHATASE, DRUG RESISTANCE, CLINICALLY ACTIONABLE, KINASE | | PANITUMUMAB | PANITUMUMAB | 19223544 |
5728 | PTEN | PTEN FAMILY, ENZYME, PROTEIN PHOSPHATASE, DRUG RESISTANCE, CLINICALLY ACTIONABLE, KINASE | | Oxaliplatin | OXALIPLATIN | 24100628 |
5728 | PTEN | PTEN FAMILY, ENZYME, PROTEIN PHOSPHATASE, DRUG RESISTANCE, CLINICALLY ACTIONABLE, KINASE | | DETD-35 | | 27048951 |
5728 | PTEN | PTEN FAMILY, ENZYME, PROTEIN PHOSPHATASE, DRUG RESISTANCE, CLINICALLY ACTIONABLE, KINASE | | cisplatin | CISPLATIN | |
5728 | PTEN | PTEN FAMILY, ENZYME, PROTEIN PHOSPHATASE, DRUG RESISTANCE, CLINICALLY ACTIONABLE, KINASE | | Copanlisib | COPANLISIB | 27672108 |
5728 | PTEN | PTEN FAMILY, ENZYME, PROTEIN PHOSPHATASE, DRUG RESISTANCE, CLINICALLY ACTIONABLE, KINASE | | Fulvestrant | FULVESTRANT | 26733612 |